Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06692933 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 31, 2025 to Aug 31, 2027
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Trial Details
NCT Number NCT06692933
Lead Sponsor Washington State University
Collaborators: Office of Dietary Supplements (ODS), National Center for Complementary and Integrative Health (NCCIH)
Conditions
(from sponsor)		 Interaction
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov